Olezarsen Shows Ability to Reduce Triglycerides for Patients with FCS in BALANCE Trial
Olezarsen shows promise in managing familial chylomicronemia syndrome, reducing triglycerides and acute pancreatitis events.
Trends in Targeted Temperature Management Before and After 2013, with José López, MD
An ACC.24 analysis found a decline in TTM use post-2013 TTM trial, which investigators suggest indicates a potential misinterpretation of trial findings.
HCPLive Five at ACC 2024
Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This edition focuses on 5 updates from the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions.
Laura Ross, PA-C: HeartBeet Clinic Offers Efficient, Reimbursable Avenue for Improving CV Risk Factors
Laura Ross, PA-C, sits down for a Q&A on the HeartBeet Clinic and the role of reimbursable group visits in cardiovascular disease management and education.
Ankeet Bhatt, MD, MBA: Sacubitril/Valsartan vs ACEi/ARB in de novo HFmrEF/HFpEF
A retrospective analysis of EHR data from ACC.24 provides insight into the effects of ARNI relative to ACEi/ARB in patients with newly diagnosed heart failure and an LVEF greater than 40%.
Safia Chatur, MD: Sacubitril/Valsartan Offers Benefit in HFrEF Across New KDIGO Risk Classes
Safia Chatur, MD, discusses the results of a PARADIGM-HF analysis at ACC.24 examining the effects of ARNI use across the updated 2024 KDIGO Risk Classifications.
Ankeet Bhatt, MD, MBA: NUDGE-FLU Analysis in Patients With and Without Myocardial Infarction
Ankeet Bhatt, MD, MBA, discusses a NUDGE-FLU analysis from ACC.24 examining effect of the CV gain-framed nudge in patients with and without history of AMI.
Understanding Trends in Hypertrophic Cardiomyopathy-Related ED Visits, with Ahmad Masri, MD, MS
Ahmad Masri, MD, MS, discusses a study from ACC.24 examining trends in incidence and outcomes of emergency department visits related to hypertrophic cardiomyopathy from 2006 to 2019.
Sara Saberi, MD: FOREST-HCM Data Demonstrates Long-Term Effects of Aficamten
Sara Saberi, MD, discusses 1-year data from a cohort of 46 patients within the FOREST-HCM trial at ACC.24.
ACC.24 Clinical Trials Recap, with Deepak Bhatt, MD, MPH, MBA
Deepak Bhatt, MD, MPH, MBA, provides a recap of top trials and new data from the American College of Cardiology's 2024 Annual Scientific Session.
Experts' Perspectives: Advancements in Cardiomyopathy at ACC.24
A trio of experts discuss their perspectives on the recent advancement in pharmacotherapy within the management of hypertrophic cardiomyopathy.
Web App Could Improve Statin Therapy Without Need for Clinician Prescription
A study on a web app for nonprescription statin therapy shows high concordance with clinician assessment, with 84.5% of participants achieving LDL-C reduction of 20% or more.
ACC.24 Case Report: Leadless Pacemaker Extractions, with José López, MD
José López, MD, discusses a case series from ACC.24 related to leadless pacemaker extraction and reimplantation.
Obicetrapib Works Synergistically with Ezetimibe in Statin Users, Study Finds
Christie Ballantyne, MD, discusses new data from the ROSE2 trial examining the potential synergistic effects of obicetrapib with ezetimibe in high-intensity statin users.
Ninerafaxstat Shows Promise in Phase 2 IMPROVE-HCM Trial for Nonobstructive HCM
Martin Maron, MD, discusses the results of the IMPROVE-HCM trial and how it informs the community on the potential of ninerafaxstat.
SHASTA-2 and Plozasiran in Severe Hypertriglyceridemia, with Christie Ballantyne, MD
Christie Ballantyne, MD, discusses data from the SHASTA-2 trial and how it informs the community on the potential of plozasiran in management of severe hypertriglyceridemia.
Modified On-Treatment Analysis Confirms Results of TRANSFORM-HF
Veraprapas Kittipibul, MD, discusses an analysis of the TRANSFORM-HF trial at ACC.24.
SGLT2 Inhibition Across a Range of Left Ventricular Hypertrophy, with Muthiah Vaduganathan, MD, MPH
Muthiah Vaduganathan, MD, MPH, discusses a presentation from ACC.24 assessing the effects of dapagliflozin across a range of left ventricular hypertrophy from DELIVER.
REDUCE-AMI: No Benefit to Beta Blockers Post-Myocardial Infarction If LVEF is Normal
REDUCE-AMI concluded beta-blockers show no significant benefit following myocardial infarction among patients with normal left ventricular ejection fraction
Alberto Foà, MD, PhD: Understanding Hypotension, Benefit, and LVEF in PARAGON-HF
Alberto Foà, MD, PhD, discusses a PARAGON-HF analysis from ACC.24 examining treatment-related hypotension in people with HFmrEF/HFpEF.
Plozasiran Reduces Triglycerides, ApoC3 in Phase 2b SHASTA-2 Trial
Plozasiran demonstrates a 74% reduction in triglyceride levels at 24 weeks in patients with severe hypertriglyceridemia in the phase 2b SHASTA-2 trial.
Understanding Total Costs Associated with Hospitalization for Heart Failure, with Veraprapas Kittipibul, MD
Veraprapas Kittipibul, MD, discusses a study examining costs associated with heart failure hospitalization among patients with HFrEF or HFpEF from within the GWTG-HF registry.
STEP HFpEF DM: Semaglutide 2.4 mg Improves Functional Status, Symptoms in Patients with Diabetes, HFpEF
The STEP HFpEF DM trial at ACC.24 shows significant improvements in symptoms among patients with obesity-related HFpEF and diabetes mellitus.
Inclisiran First Strategy Safe, Effective for LDL-C Control in ASCVD Patients
New data from a phase 3b trial presented at ACC.24 underlines the potential of inclisiran in reducing LDL-C levels among patients with ASCVD.
Don't Miss a Beat: EMPACT-MI at ACC.24, with Javed Butler, MD
In this ACC.24 episode of Don't Miss a Beat, hosts are joined by Javed Butler, MD, for a breakdown of the EMPACT-MI trial.
AEGIS-II Misses Primary Endpoint, Suggests Potential for CSL112 in Hyperlipidemia
CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.
Empagliflozin Misses Primary Endpoint in Post-MI Patient Population, EMPACT-MI Trial
Results of EMPACT-MI suggest use of empagliflozin was not associated with a statistically significant reduction in a composite of death and heart failure hospitalization.
HCPLive and APAC to Host Pre-ACC Tweet Chat
Join us April 01 on Twitter for a pre-meeting Tweet chat ahead of the American College of Cardiology's 2024 annual meeting!
Deepak Bhatt, MD, MPH: 5 Late-Breaking Trials to Watch at ACC 2024
Deepak Bhatt, MD, MPH, looks ahead to discuss what he is most excited about from the upcoming late-breaking clinical trials sessions at the American College of Cardiology 2024 annual meeting
Erin Michos, MD, MHS: Updates in Lipidology from ACC.23
Erin Michos, MD, MHS, discusses her choices for top studies in lipidology from the American College of Cardiology 2023 Scientific Sessions.
